banner
 
bar

program

slides
bar
 
 

New Frontiers and Evolving Paradigms in Cancer and Thrombosis

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium:

Internet-based program

Method of Physician Participation Utilized in Learning Process:

There are no fees for participating and receiving CME credit for this activity. During the period July 18, 2011 through July 18, 2013 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 4 segments totaling 1 hour and 40 minutes to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate

Estimated Time to Complete Educational Activity:

2.0 hours

Course Overview:

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in the prevention and management of thrombosis in the setting of cancer.

Release Date:

July 18, 2011

Expiration Date:

July 18, 2013

Intended Audience:

  • Cancer Specialists
  • Clinical Oncologists
  • Hematologists and Thrombosis Specialists
  • Oncology Program Directors
  • Oncology-focused Pharmacists
  • Nurse Oncologists
  • Oncology-Focused Nurse Practitioners

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

logoSupported by Independent Educational Grants
from sanofi-aventis

Disclosure of Conflicts of Interest:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School Office of Continuing Medical Education (UMMS-OCME) and CMEducation Resources. The UMMS-OCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Faculty and Disclosures:

PROFESSOR LORD AJAY KAKKAR, MBBS (HONS) BSC, PhD, FRCS
(Program Chairperson)
Professor and Head
Centre for Surgical Science
Dean of External Relations
Barts and the London School of Medicine and Dentistry
London, UK

Nothing to disclose

FREDERICK R. RICKLES, MD, FACP

Professor of Medicine, Pediatrics and Pharmacology and Physiology
The George Washington University
Katzen Cancer Center
Medical Faculty Associates
Washington, DC

Consultant: Eisai, Genmab, Pharmacyclics, Ortho
McNeil (J&J)/Bayer
Speaker's Bureau: Eisai



ALOK A. KHORANA, MD, FACP
Vice-Chief, Division of Hematology/Oncology
Associate Professor of Medicine and Oncology
James P. Wilmot Cancer Center
University of Rochester
Rochester, NY

Consultant: Sanofi-Aventis, Eisai, LEO Pharma,
Daiichi Sankyo
Speaker's Bureau: Roche



CRAIG KESSLER, MD, MACP
Professor of Medicine and Pathology
Georgetown University Medical Center
Director, Division of Coagulation
Lombardi Comprehensive Cancer Center
Washington, DC

Consultant: Esai, Inc., Novo Nordisk
Grant/Research Suport: Novo/Nordisk

Program Managers and Web Editor Disclosure:

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives:

Upon completion of this activity, participants will:

  1. Be better educated about established and evolving ASCO and NCCN algorithms and guidelines for screening, diagnosing, assessing, and implementing evidence-based treatment plans for patients with cancer
  2. Be better educated about what pharmacologic interventions—including those affecting the coagulation system—can be implemented to prevent and/or treat thrombotic disorders in different tumor types, and what impact anticoagulation strategies may have on other end points in cancer, including survival and tumor progression
  3. Have a better understanding the role activation of blood coagulation, and how tissue factor (TF)-rich microparticles (MPs) may be linked directly to oncogene-induced malignant transformation
  4. Have a better understanding of the role of tissue factor antigen levels and attenuated induction of cellular invasion in patients with advanced cancers (i.e., pancreatic) and the usefulness of these assays as markers to guide appropriate use of LMWHs to optimize anticancer effects of agents affecting the coagulation cascade
  5. Be better able to compare and analyze the safety, efficacy, costs of monitoring, and long-term outcomes of vitamin K antagonists versus LMWHs when managing cancer patients who require secondary prevention of VTE

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
    · If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer:

Copyright © 2011 by CMEducation Resources, LLC All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, or the program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © 2011 Resources, LLC All rights reserved

 
6

 

Key Program Topics Include:

ACCP Consensus Guidelines
Activation
Acute Illness
adhesive interactions
Akt
Angiogenesis
anticoagulants
Antithrombotic Therapy: Choices
Apixaban
ARISTOS
Armand Trousseau
ARTEMIS
AVERROES
Basement matrix
Bladder
Bleeding
Blood Coagulation
Brain
Breast
Cancer
Cancer Surgery
CANTHENOX
Central Venous Catheters
Cervix
Chemotherapy
CLOT
Clotting
Clotting dependent
Clotting independent
Coagulation
Colon

Dalteparin
Direct anti-IIa
Direct anti-Xa inhibitors
Distant
DVT
Eisai
Elastic Stockings
Endothelial
Endothelial cells
ENOXACAN
Enoxaparin
Esophagus
ETHICS
FAME
FIBRIN
Fibrinolytic
FRONTLINE
FVII/FVIIa
Gastrointestinal
Glioblastoma
Hematological
HIT
Hospitalization
Hypercoagulability
Hypoxia
IL-1
IL-8
immobilization
Inferior Vena Cava Filter
Kidney
Leukemia
Liver
LMWH

Low Molecular Weight
metastasesHeparin
Lung
Lymphoma
Malignancy
MALT
MEDENOX
medical illness (22%)
MET
Monocyte
Myeloma
Myeloprol
Nadroparin
ONCENOX
oncogene
Oncology
Ovary
PAI-1
PAI-2
Pancreas
PAR-2
Pathogenesis
Pentasaccharide
Platelets
PMN leukocyte
Pneumatic Compression
PREVENT
Procoagulant Activities
Prophylaxis
Prostate
Protease
Pseudopalisading
Pten

RadiotherapyRas
Rectal
RE-LY
rivaroxaban
ROCKET-AF
SCLC
selectin/integrin-mediated
solid tumour malignancy
Stasis
Stomach
Surgery
TF
TF si mRNA
thrombohemorrhagic syndrome
thromboprophylaxis.
Thrombosis
Tinzaparin
TNF-α,
t-PA
Tumor cells
u-PA
u-PAR
Uterus
Vascular Injury
VEGF
VEGF
Venous thromboembolism
Virchow's Triad
VTE
VTE in Hospitalized Cancer
Warfarin